Three large RCTs - SIRFLOX, FOXFIRE and FOXFIRE Global - investigated the first-line use of SIR-Spheres® Y-90 resin microspheres in addition to chemotherapy in metastatic colorectal cancer (mCRC).
Key endpoints from the SIRFLOX study were reported at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting and published in the Journal of Clinical Oncology in 2016. Overall Survival (OS) data from the three studies were presented as the FOXFIRE Combined Analysis, at the 2017 ASCO meeting. Subsequently a clinically relevant post hoc analysis addressing efficacy in patients with a right-sided primary tumor was presented at European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (WCGIC), 2017.
REsect, a retrospective, blinded evaluation of CT scans from the SIRFLOX study patient cohort on eligibility for hepatic resection, was presented at the 12th International Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), May 2017.
In addition to the SIRFLOX and FOXFIRE studies, other clinical studies are investigating the treatment of mCRC, HCC, and other unresectable liver tumours with SIR-Spheres Y-90 resin microspheres.
SIR-Spheres Y-90 resin microspheres have been extensively investigated in the treatment of liver metastases from colorectal cancer. Numerous studies, including several randomized controlled trials, have been published on the combination of SIR-Spheres Y-90 resin microspheres with chemotherapy in first and subsequent lines as well as a monotherapy for mCRC. View summary of published data for SIR-Spheres Y-90 resin microspheres in the treatment of mCRC
For important use and risk information, click here for a copy of the Instruction for Use.